Solia Eirini, Kastritis Efstathios
Department of Clinical Therapeutics, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Department of Clinical Therapeutics, Faculty of Medicine, National and Kapodistrian University of Athens, 80 Vassilisis Sofias Avenue, Athens 11527, Greece.
Ther Adv Hematol. 2024 Dec 23;15:20406207241308771. doi: 10.1177/20406207241308771. eCollection 2024.
Waldenström macroglobulinemia is an indolent B-cell lymphoma which although remains incurable, there are a lot of treatment options. Today, Bruton tyrosine kinase inhibitors have a central role in the management of the disease either as monotherapy or combination with other regimens, due to their efficacy, ease of administration, and safety profile. However, there is still active clinical investigation to further increase their efficacy and improve safety profile. Combinations based on BTK inhibitors may offer advantages. Second- and third-generation BTK inhibitors are also evaluated in combinations aiming to improve the depth of response, overcome genetic factors associated with poorer outcomes and reduce toxicity and duration of therapy.
华氏巨球蛋白血症是一种惰性B细胞淋巴瘤，尽管仍无法治愈，但有多种治疗选择。如今，布鲁顿酪氨酸激酶抑制剂因其疗效、给药便利性和安全性，在该疾病的治疗中无论是单药治疗还是与其他方案联合使用都发挥着核心作用。然而，仍有积极的临床研究以进一步提高其疗效并改善安全性。基于布鲁顿酪氨酸激酶抑制剂的联合治疗可能具有优势。第二代和第三代布鲁顿酪氨酸激酶抑制剂也在联合治疗中进行评估，旨在提高缓解深度、克服与较差预后相关的遗传因素，并降低毒性和缩短治疗持续时间。
